title: [Research progresses of monoclonal antibodies therapy in neuromyelitis optica].
abstract: Neuromyelitis optica (NMO) is a kind of demyelinating disorder that preferentially affects the optic nerves and spinal cord and results in permanent vision loss. There is no effective treatment so far. In recent years, monoclonal antibodies (mAbs) have been applied in a number of clinical drug trials and basic researches in NMO therapy due to its specificity and uniformity. Phase I clinical study found that, symptoms significantly improved in some patients after mAbs treatment. This review will expound the therapy classification, mechanism of action and clinical results involving mAbs, and provide reference for the clinical treatments of NMO.
authors.affiliation: Department of Ophthalmology, Chinese PLA General Hospital, Beijing 100853, China.
authors.forename: Shanshan
authors.initials: S
authors.lastname: Cao
authors.affiliation: Department of Ophthalmology, Chinese PLA General Hospital, Beijing 100853, China.
authors.forename: Hongyang
authors.initials: H
authors.lastname: Li
authors.affiliation: Department of Ophthalmology, Chinese PLA General Hospital, Beijing 100853, China.
authors.forename: Hao
authors.initials: H
authors.lastname: Kang
authors.affiliation: Department of Ophthalmology, Chinese PLA General Hospital, Beijing 100853, China.
authors.forename: Shuo
authors.initials: S
authors.lastname: Zhao
authors.affiliation: Department of Ophthalmology, Chinese PLA General Hospital, Beijing 100853, China; Email: weishihui706@hotmail.com.
authors.forename: Shihui
authors.initials: S
authors.lastname: Wei
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D035843:Biomedical Research; D017321:Clinical Trials, Phase I as Topic; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D009471:Neuromyelitis Optica / Q000628:therapy*; D009900:Optic Nerve; D012680:Sensitivity and Specificity
chemical_list: D000911:Antibodies, Monoclonal